Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: Discovery of MK-2918

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 9, 2011, Pages 2683-2686

  Paone, Daniel V ^a   Nguyen, Diem N ^a   Shaw, Anthony W ^a   Burgey, Christopher S ^a   Potteiger, Craig M ^a   Deng, James Z ^a   Mosser, Scott D ^a   Salvatore, Christopher A ^a   Yu, Sean ^a   Roller, Shane ^a   Kane, Stefanie A ^a   Selnick, Harold G ^a   Vacca, Joseph P ^a   Williams, Theresa M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Calcitonin gene related peptide; CGRP; Migraine; MK 2918; Telcagepant

Indexed keywords

AZABENZOXAZINONE SPIROPIPERIDINE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CAPROLACTAM; DIMETHYL ETHER; IMIDAZOAZEPANE DERIVATIVE; IMIDAZOLE; MK 2918; PIPERIDINE DERIVATIVE; TELCAGEPANT; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ANALGESICS, NON-NARCOTIC; ANIMALS; AZEPINES; BIOLOGICAL AVAILABILITY; CAPROLACTAM; CELLS, CULTURED; DOGS; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; MACACA MULATTA; MIGRAINE DISORDERS; MOLECULAR STRUCTURE; RATS; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79955466716     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.12.054     Document Type: Conference Paper

References (30)

1. P.J. Goadsby , R.B. Lipton , and M.D. Ferrari N. Engl. J. Med. 346 2002 257
2. A. Wackenfors , M. Jarvius , R. Ingemansson , L. Edvinsson , and M. Malmsjo J. Cardiovasc. Pharmacol. 45 2004 476
3. D. Dodick , R.B. Lipton , V. Martin , V. Papademetriou , W. Rosamond , A.M. VanDenBrink , H. Loutfi , K.M. Welch , P.J. Goadsby , S. Hahn , S. Hutchinson , D. Matchar , S. Silberstein , T.R. Smith , R.A. Purdy , and J. Saiers Headache 44 2004 414
4. D. van Rossum , U.-K. Hanisch , and R. Quirion Neurosci. Biobehav. Rev. 21 1997 649
5. D.R. Poyner Pharmacol. Ther. 56 1992 23
6. P.L. Durham Headache 48 2008 1269
7. L. Edvinsson Expert Opin. Ther. Targets 7 2003 377
8. L.H. Lassen , P.A. Haderslev , V.B. Jacobsen , H.K. Iversen , B. Sperling , and J. Olesen Cephalalgia 22 2002 54
9. K. Rudolf , W. Eberlein , E. Wolfhard , H. Pieper , M. Entzeroth , G. Hallermayer , and H. Doods J. Med. Chem. 48 2005 5921
10. J. Olesen , H.-C. Diener , I.W. Husstedt , P.J. Goadsby , D. Hall , U. Meier , S. Pollentier , and L. Lesko N. Engl. J. Med. 350 2004 1104
11. H. Doods , G. Hallermayer , D. Wu , M. Entzeroth , K. Rudolf , W. Engel , and W. Eberlein Br. J. Pharm. 129 2000 420
12. T.W. Ho , M.D. Ferrari , D.W. Dodick , V. Galet , J. Kost , X. Fan , H. Leibensperger , S. Froman , C. Assaid , C. Lines , H. Koppen , and P.K. Winner Lancet 372 2008 2115
13. T.W. Ho , L. Mannix , X. Fan , C. Assaid , C. Furtek , C. Jones , C. Lines , and A. Rapoport Neurology 70 2008 1305
14. T.M. Williams , C.A. Stump , D.N. Nguyen , A.G. Quigley , I.M. Bell , S.N. Gallicchio , C.B. Zartman , B.-L. Wan , K. Della Penna , P. Kunapuli , S.A. Kane , K.S. Koblan , S.D. Mosser , R.Z. Rutledge , C. Salvatore , J.F. Fay , J.P. Vacca , and S.L. Graham Bioorg. Med. Chem. Lett. 16 2006 2595
15. A.W. Shaw , D.V. Paone , D.N. Nguyen , C.A. Stump , C.S. Burgey , S.D. Mosser , C.A. Salvatore , R.Z. Rutledge , S.A. Kane , K.S. Koblan , S.L. Graham , J.V. Vacca , and T.M. Williams Bioorg. Med. Chem. Lett. 17 2007 4795
16. D.V. Paone , A.W. Shaw , D.N. Nguyen , C.S. Burgey , Z.J. Deng , S.A. Kane , K.S. Koblan , C.A. Salvatore , J.C. Hershey , B. Wong , S.G. Roller , C. Miller-Stein , S.L. Graham , J.P. Vacca , and T.M. Williams J. Med. Chem. 50 2007 5564
17. C.A. Salvatore , J.C. Hershey , H.A. Corcoran , J.F. Fay , V.K. Johnston , E.L. Moore , S.D. Mosser , C.S. Burgey , D.V. Paone , A.W. Shaw , S.L. Graham , J.P. Vacca , T.M. Williams , K.S. Koblan , and S.A. Kane JPET 324 2008 416
18. For the details of these assays see: Bell, I. M.; Graham, S. L.; Williams, T. M.; Stump, C. A. WO 2004/087649.
19. Aqueous solubilities at pH 7.4: telcagepant = 30 μg/mL; triazole 1 = 158 μg/mL.
20. As a general trend, fused heterocycles in this series with low permeability resulted in low oral exposures.
21. D.V. Paone , and A.W. Shaw Tetrahedron Lett. 49 2008 6155
22. C.S. Burgey , D.V. Paone , A.W. Shaw , J.Z. Deng , D.N. Nguyen , C.M. Potteiger , S.L. Graham , J.P. Vacca , and T.M. Williams Org. Lett. 10 2008 3235
23. S. Scheibye , B.S. Pederson , and S.O. Lawesson Bull. Soc. Chim. Belg. 87 1978 229
24. For additional synthetic details, see: Burgey, C. S.; Paone, D. V.; Shaw, A. W.; Nguyen, D. N.; Deng, Z. J.; Vacca, J. P.; Selnick, H. G.; Williams, T. M.; Potteiger, C. WO 2006/044504 A2.
25. 1H NMR, HRMS, and HPLC.
26. C.E. Raab , J.W. Butcher , T.M. Connolly , J. Karczewski , N.X. Yu , S.J. Staskiewicz , N. Liverton , D.C. Dean , and D.G. Melillo Bioorg. Med. Chem. Lett. 16 2006 1692
27. C.S. Burgey , C.M. Potteiger , J.Z. Deng , S.D. Mosser , C.A. Salvatore , S. Yu , S. Roller , S.A. Kane , J.P. Vacca , and T.M. Williams Bioorg. Med. Chem. Lett. 19 2009 6368
28. J.C. Hershey , H.A. Corcoran , E.P. Baskin , C.A. Salvatore , S. Mosser , T.M. Williams , K.S. Koblan , R. Hargreaves , and S.A. Kane Regul. Pept. 127 2005 71
29. -OH = (po normalized AUC 31 upon dosing of 30)/ (iv normalized AUC 31 upon dosing of 31).
30. Additions of both amino alcohols and amino ketones to thioamides were rapid, typically complete in <10 min. Cyclization of the intermediate amidine to 38 required and additional 18 h.